Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment

admin by admin
September 27, 2024
in Stock
0
Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Investing.com — Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company’s new schizophrenia treatment, COBENFY.

The drug, which combines xanomeline and trospium chloride, represents a major breakthrough, with the company claiming it is the first new pharmacological approach to treat schizophrenia in decades.

COBENFY is a muscarinic agonist that targets M1 and M4 receptors, offering a new mechanism of action distinct from current therapies.

Chris Boerner, CEO of Bristol-Myers Squibb, described the approval as a “landmark.”

“After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm,” he said in a statement.

The approval is based on data from the EMERGENT clinical program, which demonstrated “significant reductions of schizophrenia symptoms compared to placebo.”

The drug is also said to have a favorable safety profile. Analysts see this as a positive development for COBENFY’s market potential.

Barclays analysts said the news validates the company’s acquisition of Karuna and gives “Bristol another key top-line driver over the balance of the decade.”

They added that the drug’s list price of $1,850 per month (~$22,500 annually) suggests potential upside beyond their initial expectations.

Truist analysts emphasized the first-in-class status of COBENFY, noting that it is the first new mechanism of action approved for schizophrenia in over 30 years.

They estimate that the drug could generate $4.2 billion in peak sales, surpassing the consensus estimate of $3.9 billion. The analysts also highlighted Bristol-Myers’ future plans to expand COBENFY’s indications to include Alzheimer’s-related psychosis and bipolar disorder.

Meanwhile, BMO Capital told investors in a note that the news is a “significant positive for BMY shares.”

“Today’s announcement validates Bristol’s $12.7B acquisition of Karuna and allows the company to start changing the narrative around the ongoing triple patent-cliff,” said BMO Capital. “Following today’s approval we estimate $2.4B in peak sales for COBENFY in Schizophrenia and $3.9B in Alz psychosis, pushing our target to $53/share.”

This post appeared first on investing.com

Previous Post

China cuts short-term borrowing costs

Next Post

Ceres surges after ‘solid numbers update’

admin

admin

Next Post
Ceres surges after ‘solid numbers update’

Ceres surges after ‘solid numbers update’

Trending News

Top gainers & losers today: Nifty, Sensex jump 2%, metals in the spotlight

Top gainers & losers today: Nifty, Sensex jump 2%, metals in the spotlight

April 12, 2025
Care for pet dog, provisions for butler: what’s inside Ratan Tata’s will?

Care for pet dog, provisions for butler: what’s inside Ratan Tata’s will?

October 25, 2024
US stocks slip in the red on Monday: Dow down 100 points, S&P drops 0.5%

US stocks slip in the red on Monday: Dow down 100 points, S&P drops 0.5%

May 19, 2025
Subscribe to Insightful Word


    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025
    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    August 28, 2025
    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    August 28, 2025

    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025

    Latest News

    • Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in
    • SentinelOne stock price forecast ahead of earnings: buy or sell?
    • Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.